Evidence map›Paper›PMID 39205071›Full record

ArticleSensors (Basel, Switzerland)2024

Targeted FT-NIR and SERS Detection of Breast Cancer HER-II Biomarkers in Blood Serum Using PCB-Based Plasmonic Active Nanostructured Thin Film Label-Free Immunosensor Immobilized with Directional GNU-Conjugated Antibody.

Mohammad E Khosroshahi, Yesha Patel, Vithurshan Umashanker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammad E KhosroshahiNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.ORCID 0000-0002-6628-5569
Yesha PatelNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.
Vithurshan UmashankerNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.

Funding

MIS Electronics Inc. 0
6 · The paper itself

Abstract

This work describes our recent PCB-based plasmonic nanostructured platform patent (US 11,828,747B2) for the detection of biomarkers in breast cancer serum (BCS). A 50 nm thin gold film (TGF) was immersion-coated on PCB (i.e., PCB-TGF) and immobilized covalently with gold nanourchin (GNU) via a 1,6-Hexanedithiol (HDT) linkage to produce a plasmonic activated nanostructured thin film (PANTF) platform. A label-free SERS immunosensor was fabricated by conjugating the platform with monoclonal HER-II antibodies (mAb) in a directional orientation via adipic acid dihydrazide (ADH) to provide higher accessibility to overexpressed HER-II biomarkers (i.e., 2+ (early), 3+ (locally advanced), and positive (meta) in BCS. An enhancement factor (EF) of 0.3 × 10

Indexed as

Biomarkers, TumorBreast NeoplasmsGoldNanostructuresSpectrum Analysis, RamanAntibodies, ImmobilizedBiosensing TechniquesErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoassayMetal NanoparticlesSpectroscopy, Fourier Transform InfraredSpectroscopy, Near-InfraredAntibodies, ImmobilizedBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGoldbiomarkerbreast cancerdirectional antibodygold nanourchinshuman serumSERS

Identifiers

PMID39205071
PMCPMC11358943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.